Post-Marketing Safety Study in Japan of Shock and Anaphylaxis After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons in at High Risk of Severe COVID-19
Clinical trial NCT05894499 · COMPLETED
Trial details
- NCT number
- NCT05894499
- Sponsor
- ModernaTX, Inc.
- Status
- COMPLETED
- Study type
- OBSERVATIONAL
- Start date
- 2022-11-15
- Primary completion
- 2023-05-26
- Enrollment
- 13309
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.